MRIdian clinical studies and first clinical experiences with MRIdian A3i will be presented at ASTRO 2022

Oral presentations on the clinical results of the SMART pancreas and MIRAGE prostate studies

DENVER, October 19, 2022 /PRNewswire/ — ViewRay, Inc. (NASDAQ: VRAY) announced today that the company’s MRIdian® MRI-guided radiation therapy system will be presented at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO), to be held on October 23 will be held at the Henry B. González Convention Center in San Antonio, Texas on -26-26, 2022. The meeting will feature numerous presentations and posters highlighting MRIdian’s state-of-the-art stereotactic MRI-guided adaptive radiation therapy (SMART), including oral presentations presenting results from the multi-center SMART Pancreas study and MIRAGE, a phase III randomized controlled prostate study. In addition, the first clinical experiences with MRIdian A3i will be presented during the conference.

On Tuesday, October 25, 2022 at 3:00 p.m. CT, Dr. Parag Parikh of the Henry Ford Health System delivered an oral presentation entitled “Stereotactic MR-Guided On-Table Adaptive Therapy (SMART) for Patients with Borderline or Locally Advanced Pancreatic Cancer: Primary Endpoint Results of a Prospective Multicenter International Phase II Trial.” The SMART study (NCT03621644) is a prospective clinical study evaluating the clinical utility of ablative MR-guided radiation therapy in the treatment of borderline resectable or unresectable locally advanced pancreatic cancer.

On Wednesday, October 26, 2022 at 11:00 a.m. CT, Dr. Amar Kishan from UCLA gave an oral presentation titled “Magnetic Resonance Imaging-Guided vs. Computed Tomography-Guided Stereotactic Body Irradiation in Prostate Cancer (MIRAGE): Primary Endpoint Analysis of a Randomized Phase III Trial”. This clinical study compared MRIdian MRI-guided SBRT to CT-guided SBRT in localized prostate cancer. At the ASCO GU 2022, Dr. Kishan on the preliminary results and analysis of the primary endpoint that signaled the superiority of MRI-guided MRI-guided SBRT compared to CT-guided SBRT. During this presentation he will present the final results of acute GU and GI toxicity.

In addition, there will be dozens of scientific session presentations and posters highlighting the important role of MRIdian in cancer treatment, including data demonstrating its clinical value in the treatment of cancers such as pancreas, prostate, bladder, liver, kidney and lung, including Ultra , demonstrate central lung lesions and oligometastatic diseases. There will also be presentations focusing on the benefits of MRIdian in delivering re-irradiation and adaptive on-table therapy.

On Monday, October 24, 2022 at 4:00 p.m. CT, ViewRay will host an Industry Expert Theater entitled “MRIdian A3i – Latest innovation from MRgRT for prostate, pancreas and brain” with experts from the Henry Ford Health System and the Miami Cancer Institute who share their first clinical experience treating patients with MRIdian A3i.

The new MRIdian A3i features allow physicians to simultaneously collaborate and connect remotely during patient care. The new automated workflow and contouring tools are designed to minimize physician time and increase patient throughput. MRIdian A3i also extends the existing real-time tissue tracking and automated beam gating functionalities with multi-planar 3D tracking and gating in up to three planes.

On Sunday evening, October 23, 2022 at 6:30 p.m. CT, ViewRay is hosting as part of ViewRay’s previously announced national awareness campaign and partnership with Katie Couric Media to educate patients and physicians about MRIdian SMART. Couric will moderate a discussion with ViewRay CEO Scott Drake and radiation oncologists treating patients with MRIdian.

ViewRay will also host customer presentations throughout the conference at the company’s booth #3770, where customers will share their clinical experience treating patients with MRIdian.

MRIdian offers radiation oncologists excellent anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the target cancer while the patient is lying on the treatment table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs and healthy tissue, and enables the delivery of ablative doses of radiation in five or fewer treatment sessions without relying on implanted markers. By providing continuous, real-time tracking of the target and organs at risk, MRIdian enables automatic radiation beam blanking when the target moves outside user-defined limits. This allows the prescribed dose to be delivered to the target while sparing surrounding healthy tissue and critical structures, resulting in minimization of the toxicities typically associated with conventional radiation therapy.

To date, over 25,000 patients have been treated with MRIdian. There are currently 54 MRIdian systems installed in hospitals around the world, where they are used to treat a variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. For a list of treatment centers go to:


Nothing in this material is intended to provide specific medical advice or to supersede any written law or regulation.

Security Statement

The MRIdian Linac system is not suitable for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments can cause side effects, which vary depending on the part of the body being treated. The most common are typically transient and may include, but are not limited to, irritation of the respiratory, digestive, urinary, or reproductive systems; Fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be serious. Treatment sessions can vary in complexity and duration. Radiation treatment is not suitable for all types of cancer. You should discuss the possible side effects and their severity, as well as the benefits of radiation and magnetic resonance imaging with your doctor to ensure that radiation treatment is appropriate for you.

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY) develops, manufactures and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is based on a proprietary high-resolution MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-resolution MR is specifically designed to address specific challenges, including beam distortion, skin toxicity, and other concerns that may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, but are not limited to, ViewRay’s financial guidance for full year 2022, anticipated future orders, anticipated future operational and financial performance, patient outcomes, therapy adoption, innovation and the performance of the MRIdian systems. Actual results could differ from those projected in the forward-looking statements due to a number of factors. These factors include, but are not limited to, the ability to commercialize the MRIdian linac system, demand for ViewRay’s products, ability to convert backlogs into revenue, timing of delivery of ViewRay’s products, timing, length and severity of the COVID-19 pandemic, including the impact on our on-demand businesses, operations and global supply chains, results and other uncertainties related to clinical trials, the ability to raise the additional funds needed to sustain business and ViewRay’s product development plans, the inherent uncertainties associated with the development of new products or technologies, competition in the industry in which ViewRay operates and general market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks associated with ViewRay’s business generally, please see ViewRay’s current and future reports, which are available at with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2021 and its quarterly reports on Form 10-Q, which are regularly updated with the Company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay undertakes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

View original content: html

SOURCE ViewRay, Inc.

Comments are closed.